- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03548974
Internet-based MOTOmed Exercise to Reduce Spasticity and Improve Physical Function in Persons With Multiple Sclerosis
Internet-based Physical Activity Promotion Using the MOTOmed Movement Trainer to Reduce Spasticity and Improve Physical Function in Moderately to Severely Affected Persons With Multiple Sclerosis
In an RCT, the effect of the MOTOmed movement trainer (Reck, Germany) on spasticity and physical function in pwMS with EDSS score between 4,5 and 7 is investigated. All subjects exercise at home and are supervised and supported by an exercise therapist via an online platform.
We compare the effect of a 12 week passive, motor-driven movement therapy (VG1) to an intermittent active and passive training (VG2). After 12 weeks, VG1 continues with an active training including strengthening exercises for another 12 weeks. VG2 does not receive any intervention in the second study phase.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
diagnosed Multiple Sclerosis (McDonald criteria) EDSS score between 5,5 and 7 diagnosed spasticity access to the internet
Exclusion Criteria:
lack of medical certificate for physical activity cognitive impairment clinically relevant internal disease, especially cardiovascular or pulmonary disease, metabolic and orthopedic diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Interventiongroup1
passive, motor-driven movement therapy followed by intermittent active and passive training
|
The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment.
Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale.
Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard).
The exercise training was home-based and supervised via the internet.
|
|
ACTIVE_COMPARATOR: Interventiongroup2
intermittent active and passive training followed by no intervention
|
The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in spasticity: MSSS-88
Time Frame: Assessments took place at baseline, at 3 and 6 months
|
This questionnaire contains 88 items, which represent the impairment by the spasticity in various subscales.
The total score ranges from 88 to a maximum of 352 points (maximum impairment).
|
Assessments took place at baseline, at 3 and 6 months
|
|
Change in sSpasticity: Modified Tardieu scale
Time Frame: Assessments took place at baseline, at 3 and 6 months
|
The scale is measuring spasticity as response to passive movement at both slow and fast speed; scored 0 - 4. (0=no resistance; 4= inexhaustible clonus)
|
Assessments took place at baseline, at 3 and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in function: 5-Chair-Rise
Time Frame: Assessments took place at baseline, at 3 and 6 months
|
The main task in this test is to get up and sit down 5 times as fast as possible without use of the arms.
The goal is the global assessment of the strength of the lower limb.
|
Assessments took place at baseline, at 3 and 6 months
|
|
Change in function: 25foot-walk-test
Time Frame: Assessments took place at baseline, at 3 and 6 months
|
The task is to walk a 25foot distance as fast as possible.
This test measures the functionality of the lower extremity and the walking speed.
|
Assessments took place at baseline, at 3 and 6 months
|
|
Change in function: 2min-walk
Time Frame: Assessments took place at baseline, at 3 and 6 months
|
The subject is asked to walk with the fastest, possible speed to cover the greatest possible distance in 2min.
|
Assessments took place at baseline, at 3 and 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Manifestations
- Muscle Hypertonia
- Multiple Sclerosis
- Sclerosis
- Muscle Spasticity
Other Study ID Numbers
- ATRT-2015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Treatment group 1
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
Fundacion para la Investigacion Biomedica del Hospital...Completed
-
Amsterdam UMC, location VUmcGE HealthcareNot yet recruiting
-
Mihaela VisoiuCompletedPain, PostoperativeUnited States
-
Rush University Medical CenterPfizerTerminatedBack Pain | Chronic Pain | Pain, IntractableUnited States
-
Summa Health SystemTerminatedAdvanced Bulky MalignanciesUnited States
-
Riphah International UniversityCompleted
-
Kanyos Bio, Inc., a wholly-owned subsidiary of...PfizerCompletedCeliac Disease | Coeliac DiseaseUnited States, Canada, Finland, Ireland, Israel, Poland, Germany, Netherlands
-
University Hospitals Cleveland Medical CenterWithdrawn
-
University of Western Ontario, CanadaCompletedDepression | Breast Cancer | AnxietyCanada